skip to Main Content

Liposomal Irinotecan Regimen Pushes Toward Frontline Treatment in Metastatic Pancreatic Cancer

Liposomal Irinotecan Regimen Pushes Toward Frontline Treatment in Metastatic Pancreatic Cancer
Among limited options, moving effective therapies into earlier lines of treatment is an area of significant interest in metastatic pancreatic cancer, said Dae Won Kim, MD.

In October 2015, the FDA approved liposomal irinotecan (Onivyde) in combination with 5-fluorouracil (5-FU)/leucovorin for the treatment of patients with metastatic pancreatic cancer following prior gemcitabine-based chemotherapy, according to findings from the pivotal phase 3 NAPOLI-1 trial. Read more . . . 


Back To Top